Xenetic Biosciences
Filed with the SEC on · accession 0001683168-26-008628
XBIO filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. Xenetic Biosciences filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results including royalty revenue and operating expenses. The stock moved -9.2% by the first close after the filing.
Xenetic Biosciences filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results including royalty revenue and operating expenses. The filing provides standard quarterly financial disclosures for the company.
Close before
$1.84
Nov 11, 2026
First close after
-9.24%
$1.67
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for XBIO, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for XBIO?
Click hereXBIO filed a 10-Q (SEC filing). Xenetic Biosciences filed its quarterly report on Form 10-Q for the period ended September 30, 2026, reporting financial results including royalty revenue and operating expenses. The filing provides standard quarterly financial disclosures for the company.
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
XBIO closed at $1.84 before the filing and $1.67 on Nov 12, 2026 (-9.24%).
Get alerts when XBIO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days